AR110057A1 - Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld / nash) - Google Patents
Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld / nash)Info
- Publication number
- AR110057A1 AR110057A1 ARP170103142A ARP170103142A AR110057A1 AR 110057 A1 AR110057 A1 AR 110057A1 AR P170103142 A ARP170103142 A AR P170103142A AR P170103142 A ARP170103142 A AR P170103142A AR 110057 A1 AR110057 A1 AR 110057A1
- Authority
- AR
- Argentina
- Prior art keywords
- nafld
- nash
- treatment
- pirfenidone
- esteatohepatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Uso de una composición farmacéutica en forma de comprimidos de liberación prolongada que contienen pirfenidona para el tratamiento de NAFLD / NASH y la fibrosis hepática avanzada, mediante la disminución sérica de colesterol y triglicéridos, así como la disminución del contenido del acúmulo de grasa hepática, tanto en la forma macroesteatosis como microesteatosis. Uso como agonista para PPARg (peroxisoma proliferación receptor activado g), PPARa (peroxisoma proliferación receptor activado a), LXR y CPT1, moléculas clave en el metabolismo de degradación de las grasas e inflamación hepáticas. Asimismo, otro uso adicional consiste en la inducción de la disminución de la expresión del gen maestro NFkB, factor transcripcional inductor del proceso inflamatorio hepático. Todos estos eventos resultan en la reversión de NAFLD / NASH y la fibrosis hepática avanzada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2016014775A MX364040B (es) | 2016-11-11 | 2016-11-11 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110057A1 true AR110057A1 (es) | 2019-02-20 |
Family
ID=61193005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103142A AR110057A1 (es) | 2016-11-11 | 2017-11-10 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld / nash) |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20190262325A1 (es) |
| EP (1) | EP3539537A1 (es) |
| JP (2) | JP2019535822A (es) |
| KR (2) | KR20190084056A (es) |
| CN (2) | CN115969802A (es) |
| AR (1) | AR110057A1 (es) |
| AU (2) | AU2017358367B2 (es) |
| CA (1) | CA3043300A1 (es) |
| CL (1) | CL2019001280A1 (es) |
| CO (1) | CO2019004799A2 (es) |
| EC (1) | ECSP19031851A (es) |
| IL (1) | IL266519A (es) |
| JO (1) | JOP20190102A1 (es) |
| MA (1) | MA45754A1 (es) |
| MX (1) | MX364040B (es) |
| PE (1) | PE20191149A1 (es) |
| PH (1) | PH12019501047A1 (es) |
| RU (1) | RU2019116422A (es) |
| UY (1) | UY37478A (es) |
| WO (1) | WO2018088886A1 (es) |
| ZA (1) | ZA201903012B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
| EP3716975A4 (en) * | 2017-11-28 | 2022-01-12 | Eiger Biopharmaceuticals, Inc. | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS |
| WO2020115774A1 (en) | 2018-12-06 | 2020-06-11 | Cipla Limited | High drug load extended release formulations |
| WO2022087435A1 (en) * | 2020-10-23 | 2022-04-28 | Hq Han | Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof |
| CN116159056A (zh) * | 2023-03-09 | 2023-05-26 | 中南大学湘雅医院 | 一种氟非尼酮在制备非酒精性脂肪性肝炎药物中的应用 |
| CN117007806A (zh) * | 2023-09-21 | 2023-11-07 | 中国人民解放军军事科学院军事医学研究院 | 靶向肝巨噬细胞内lxr用于控制慢乙肝进展 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100777169B1 (ko) * | 2001-01-29 | 2007-11-16 | 시오노기세이야쿠가부시키가이샤 | 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제 |
| WO2005000227A2 (en) * | 2003-06-06 | 2005-01-06 | Intermune, Inc. | Methods of treating tnf-mediated disorders |
| CN100542532C (zh) * | 2004-05-24 | 2009-09-23 | 上海睿星基因技术有限公司 | 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途 |
| US20110288134A1 (en) * | 2008-10-29 | 2011-11-24 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
| US7635707B1 (en) * | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| CN101972236A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
| MX2011007675A (es) * | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| CN102488660A (zh) * | 2011-12-15 | 2012-06-13 | 西安天一秦昆制药有限责任公司 | 一种含吡非尼酮的缓释微丸 |
| CN103550242B (zh) * | 2013-11-22 | 2015-07-15 | 四川国康药业有限公司 | 一种治疗肝纤维化的药物组合物及其制备方法 |
-
2016
- 2016-11-11 MX MX2016014775A patent/MX364040B/es active IP Right Grant
-
2017
- 2017-06-16 JO JOP/2019/0102A patent/JOP20190102A1/ar unknown
- 2017-11-09 MA MA45754A patent/MA45754A1/fr unknown
- 2017-11-09 RU RU2019116422A patent/RU2019116422A/ru unknown
- 2017-11-09 CN CN202211265065.XA patent/CN115969802A/zh active Pending
- 2017-11-09 AU AU2017358367A patent/AU2017358367B2/en active Active
- 2017-11-09 CA CA3043300A patent/CA3043300A1/en active Pending
- 2017-11-09 JP JP2019547064A patent/JP2019535822A/ja active Pending
- 2017-11-09 KR KR1020197014274A patent/KR20190084056A/ko not_active Ceased
- 2017-11-09 UY UY0001037478A patent/UY37478A/es not_active Application Discontinuation
- 2017-11-09 KR KR1020247015017A patent/KR20240065330A/ko not_active Ceased
- 2017-11-09 CN CN201780076430.3A patent/CN110248646A/zh active Pending
- 2017-11-09 PE PE2019000946A patent/PE20191149A1/es unknown
- 2017-11-09 US US16/348,189 patent/US20190262325A1/en not_active Abandoned
- 2017-11-09 WO PCT/MX2017/000129 patent/WO2018088886A1/es not_active Ceased
- 2017-11-09 EP EP17840578.3A patent/EP3539537A1/en active Pending
- 2017-11-10 AR ARP170103142A patent/AR110057A1/es unknown
-
2019
- 2019-05-08 IL IL266519A patent/IL266519A/en unknown
- 2019-05-08 EC ECSENADI201931851A patent/ECSP19031851A/es unknown
- 2019-05-09 CL CL2019001280A patent/CL2019001280A1/es unknown
- 2019-05-10 CO CONC2019/0004799A patent/CO2019004799A2/es unknown
- 2019-05-10 PH PH12019501047A patent/PH12019501047A1/en unknown
- 2019-05-14 ZA ZA2019/03012A patent/ZA201903012B/en unknown
-
2022
- 2022-09-26 JP JP2022152261A patent/JP2022173344A/ja active Pending
- 2022-11-02 US US18/051,937 patent/US20230181550A1/en not_active Abandoned
-
2024
- 2024-02-07 AU AU2024200737A patent/AU2024200737A1/en not_active Abandoned
- 2024-12-02 US US18/965,593 patent/US20250325530A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12019501047A1 (en) | 2019-12-11 |
| UY37478A (es) | 2018-05-31 |
| US20230181550A1 (en) | 2023-06-15 |
| EP3539537A1 (en) | 2019-09-18 |
| KR20190084056A (ko) | 2019-07-15 |
| ZA201903012B (en) | 2020-09-30 |
| WO2018088886A1 (es) | 2018-05-17 |
| CN110248646A (zh) | 2019-09-17 |
| JP2022173344A (ja) | 2022-11-18 |
| MX364040B (es) | 2019-04-11 |
| IL266519A (en) | 2019-07-31 |
| KR20240065330A (ko) | 2024-05-14 |
| ECSP19031851A (es) | 2019-06-30 |
| US20190262325A1 (en) | 2019-08-29 |
| AU2024200737A1 (en) | 2024-02-22 |
| AU2017358367B2 (en) | 2023-11-09 |
| PE20191149A1 (es) | 2019-09-02 |
| US20250325530A1 (en) | 2025-10-23 |
| CN115969802A (zh) | 2023-04-18 |
| AU2017358367A1 (en) | 2019-05-30 |
| RU2019116422A3 (es) | 2021-04-09 |
| CL2019001280A1 (es) | 2019-07-19 |
| JOP20190102A1 (ar) | 2019-05-06 |
| CO2019004799A2 (es) | 2019-07-31 |
| CA3043300A1 (en) | 2018-05-17 |
| MX2016014775A (es) | 2018-05-10 |
| JP2019535822A (ja) | 2019-12-12 |
| MA45754A1 (fr) | 2019-12-31 |
| RU2019116422A (ru) | 2020-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110057A1 (es) | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld / nash) | |
| CR20170129A (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| IL259950B (en) | Pyrimidine derivatives for use in the treatment of cancer and inflammatory diseases | |
| IL256085B (en) | A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment | |
| LU92578B1 (fr) | Nouveaux composés et compostions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose | |
| LU92577B1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose | |
| MX2015014656A (es) | Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas. | |
| HRP20190573T1 (hr) | Piranokromenil fenol derivat, i farmaceutska kompozicija za liječenje metaboličkog sindroma ili inflamatorne bolesti | |
| EP3113764A4 (en) | Pharmaceutical composition for transmucosal delivery and methods for treating diabetes in a subject in need thereof | |
| IL272457A (en) | GLP-1/Glucagon agonist receptors in the treatment of fatty liver disease and steatohepatitis | |
| BR112016021034A2 (pt) | Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit | |
| PE20200444A1 (es) | Terapia de combinacion para cancer de prostata | |
| EP2949333A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF THERMAL INJURIES AND WOUNDS COMBINED WITH BONE LESIONS | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида | |
| MX2018005628A (es) | Tratamientos de grasa acumulada con acido desoxicolico y sales del mismo. | |
| CL2015001936A1 (es) | Composición y su uso que sirve para preparar un medicamento útil para tratar enfermedades relacionadas con el factor inducible por hipoxia (hif). | |
| MX2020001428A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| IL280389A (en) | Bile acid receptor modulators conjugated to G.1 protein and methods of using them | |
| IL249440A0 (en) | Compounds, pharmaceutical preparations and their use in the treatment of neurodegenerative diseases | |
| GB201410869D0 (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| AR130700A2 (es) | Composiciones de grapiprant y métodos para su utilización | |
| AR099681A1 (es) | Composiciones de grapiprant y métodos para su utilización | |
| BR112018016725A2 (pt) | composição farmacêutica para prevenir e tratar transtornos do sono | |
| HK1233946A1 (en) | Topical composition for use in the treatment of inflammatory bowel disease | |
| TH1401007652A (th) | อะมิโนไตรอะโซโลไพริดีนสำหรับการใช้ในการรักษาการอักเสบ และองค์ประกอบทางเภสัชกรรมของมัน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |